Wachtell, Goodwin Rep In Regeneron's $250M Biopharma Buy
By McCord Pagan · April 19, 2022, 5:03 PM EDT
Regeneron Pharmaceuticals Inc., guided by Wachtell Lipton Rosen & Katz, said Tuesday it is buying Goodwin Procter LLP-advised clinical-stage Checkmate Pharmaceuticals Inc. for $250 million....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login